NCT06279754View on ClinicalTrials.gov

Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 18, 2024

Primary Completion Date

June 18, 2024

Study Completion Date

December 18, 2025

Conditions
Locally Advanced Squamous Non-small Cell Lung Cancer
Interventions
DRUG

Recombinant Human Endostatin Injection

Recombinant Human Endostatin Injection：210 mg, intravenous infusion for 72 hours, once every three weeks cycle Evafolimab Injection：Subcutaneous injection on day 1, 8, and 15, once every three weeks cycle

All Listed Sponsors
lead

The First Affiliated Hospital of Xinxiang Medical College

OTHER

NCT06279754 - Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy | Biotech Hunter | Biotech Hunter